Review: CRISPR-Augmented Oncolytic Virotherapy as an Effective Treatment of Metastatic Cancer
Journal: International Journal of Science and Research (IJSR) (Vol.11, No. 10)Publication Date: 2022-10-05
Authors : Athmika Krishnan;
Page : 470-480
Keywords : cancer immunotherapy; oncolytic viruses; metastatic cancer;
Abstract
Oncolytic viruses (OVs) preferentially infect and induce lysis in cancer cells. They have been well tested as a monotherapy and in combination with other immunotherapies to treat isolated tumors. In comparison to other immunotherapies and current cancer treatments, oncolytic virotherapy offers an excellent safety profile, dual-action treatment, and potential for more targeted treatment with genetic modification. However, T-VEC, the only FDA-approved oncolytic virus drug, is limited in its application to other types of cancer by adverse effects and contraindications. In addition, the application of oncolytic virotherapy to treat metastatic cancer is under-discussed, despite its potential to improve the current poor prognosis. In this literature review, we will examine the role of CRISPR-Cas9 gene editing in creating more targeted, efficient oncolytic viruses and their clinical application to metastatic cancer.
Other Latest Articles
- Condition of Coral Reef Ecosystem Cover in the Selayar Islands Marine Protected Area
- Immediate Effect of Laughter Yoga on Blood Pressure in Elevated Blood Pressure
- Exogenous Formaldehyde in the Exacerbation of Coronary Artery Disease: An Observational Study with Meta - Analysis
- Synthesis of Chitosan and Carrageenan based Hydrogels for pH Sensing, Urea Adsorption and Dye Adsorption
- Research Paradigms: Qualitative, Quantitative and Mixed Method
Last modified: 2025-09-22 21:31:24